Blood Pressure Monitoring and Management

Assessment and Follow-up

Complete reassessment is recommended after 3-4 months of therapy, as suggested by the European Society of Cardiology 1
Home blood pressure monitoring twice daily is recommended to assess effectiveness 2, 3

The American Academy of Pediatrics recommends an initial dose of 2.5 mg daily for children 6-17 years, with a maximum dose of 5 mg daily 2
The maximum dose for adults is 10 mg daily, according to the American Academy of Pediatrics 2, 3
Amlodipine can be taken at any time of day, but consistent timing improves adherence, and it may be taken with or without food 2

Amlodipine provides significant reductions in blood pressure, with mean reductions of 23/13 mmHg in supine position and 24/12 mmHg standing, 24 hours after the last dose 4, 5
Amlodipine is well-tolerated compared to clinical doses of atenolol, hydrochlorothiazide, or verapamil, does not produce orthostatic hypotension, and there is no evidence of tolerance with long-term administration 4, 5

Amlodipine can be safely combined with ACE inhibitors, angiotensin receptor blockers, thiazide diuretics, and beta-blockers, as recommended by the European Heart Journal 6
The European Heart Journal recommends considering initial combination therapy with an ACE inhibitor, angiotensin receptor blocker, or thiazide diuretic for patients with stage 2 or 3 hypertension 6
Use caution with CYP3A4 inhibitors and inducers, as they may increase or decrease amlodipine levels, respectively 6

For pulmonary arterial hypertension, amlodipine should only be used in patients who demonstrate acute vasoreactivity, with doses up to 20 mg daily, and close follow-up required after 3 months to assess response, as recommended by the Chest journal 7

The American Heart Association and the European Society of Cardiology support once-daily dosing of amlodipine for hypertension, due to its long half-life of 40-60 hours, allowing for adequate blood pressure control over 24 hours with a single daily dose 4, 8
Amlodipine has a prolonged elimination half-life, enabling complete coverage over 24 hours, and reaches a steady state with daily administration within 1-1.5 weeks, with high oral bioavailability (60-80%) 4, 8